These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38741480)

  • 21. Oxidative DNA Damage by N4-hydroxycytidine, a Metabolite of the SARS-CoV-2 Antiviral Molnupiravir.
    Kobayashi H; Mori Y; Ahmed S; Hirao Y; Kato S; Kawanishi S; Murata M; Oikawa S
    J Infect Dis; 2023 Apr; 227(9):1068-1072. PubMed ID: 36461940
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molnupiravir: A Versatile Prodrug against SARS-CoV-2 Variants.
    Teli D; Balar P; Patel K; Sharma A; Chavda V; Vora L
    Metabolites; 2023 Feb; 13(2):. PubMed ID: 36837928
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice.
    Sheahan TP; Sims AC; Zhou S; Graham RL; Pruijssers AJ; Agostini ML; Leist SR; Schäfer A; Dinnon KH; Stevens LJ; Chappell JD; Lu X; Hughes TM; George AS; Hill CS; Montgomery SA; Brown AJ; Bluemling GR; Natchus MG; Saindane M; Kolykhalov AA; Painter G; Harcourt J; Tamin A; Thornburg NJ; Swanstrom R; Denison MR; Baric RS
    Sci Transl Med; 2020 Apr; 12(541):. PubMed ID: 32253226
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of ß-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
    FitzGerald R; Dickinson L; Else L; Fletcher T; Hale C; Amara A; Walker L; Penchala SD; Lyon R; Shaw V; Greenhalf W; Bullock K; Lavelle-Langham L; Reynolds H; Painter W; Holman W; Ewings S; Griffiths G; Khoo S
    Clin Infect Dis; 2022 Aug; 75(1):e525-e528. PubMed ID: 35271729
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decoding molnupiravir-induced mutagenesis in SARS-CoV-2.
    Menéndez-Arias L
    J Biol Chem; 2021 Jul; 297(1):100867. PubMed ID: 34118236
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Uridine-cytidine kinase 2 potentiates the mutagenic influence of the antiviral β-d-N4-hydroxycytidine.
    Xu Z; Flensburg C; Bilardi RA; Majewski IJ
    Nucleic Acids Res; 2023 Dec; 51(22):12031-12042. PubMed ID: 37953355
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis and Antiviral Activity of Novel β-D-N4-Hydroxycytidine Ester Prodrugs as Potential Compounds for the Treatment of SARS-CoV-2 and Other Human Coronaviruses.
    Darnotuk ES; Siniavin AE; Shastina NS; Luyksaar SI; Inshakova AM; Bondareva NE; Zolotov SA; Lubenec NL; Sheremet AB; Logunov DY; Zigangirova NA; Gushchin VA; Gintsburg AL
    Pharmaceuticals (Basel); 2023 Dec; 17(1):. PubMed ID: 38256869
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and anti-SARS-CoV-2 evaluation of lipid prodrugs of β-D-N
    Wen ZH; Wang MM; Li LY; Herdewijn P; Snoeck R; Andrei G; Liu ZP; Liu C
    Bioorg Chem; 2023 Jun; 135():106527. PubMed ID: 37031504
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molnupiravir: A lethal mutagenic drug against rapidly mutating severe acute respiratory syndrome coronavirus 2-A narrative review.
    Masyeni S; Iqhrammullah M; Frediansyah A; Nainu F; Tallei T; Emran TB; Ophinni Y; Dhama K; Harapan H
    J Med Virol; 2022 Jul; 94(7):3006-3016. PubMed ID: 35315098
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A validated LC-MS/MS method for determination of antiviral prodrug molnupiravir in human plasma and its application for a pharmacokinetic modeling study in healthy Egyptian volunteers.
    Gouda AS; Marzouk HM; Rezk MR; Salem AM; Morsi MI; Nouman EG; Abdallah YM; Hassan AY; Abdel-Megied AM
    J Chromatogr B Analyt Technol Biomed Life Sci; 2022 Aug; 1206():123363. PubMed ID: 35810537
    [TBL] [Abstract][Full Text] [Related]  

  • 31. β-d-
    Urakova N; Kuznetsova V; Crossman DK; Sokratian A; Guthrie DB; Kolykhalov AA; Lockwood MA; Natchus MG; Crowley MR; Painter GR; Frolova EI; Frolov I
    J Virol; 2018 Feb; 92(3):. PubMed ID: 29167335
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molnupiravir: an antiviral drug against COVID-19.
    Dave B; Shah KC; Chorawala MR; Shah N; Patel P; Patel S; Shah P
    Arch Virol; 2023 Sep; 168(10):252. PubMed ID: 37710056
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of pharmacokinetics, safety, and tolerability following twice-daily administration of molnupiravir for 10 days in healthy participants.
    Iwamoto M; Duncan KE; Wickremasingha PK; Zhao T; Liberti MV; Lemoine L; Decaesteker T; Rottey S; Maas BM; Gillespie G; Stoch SA
    Clin Transl Sci; 2023 Oct; 16(10):1947-1956. PubMed ID: 37526305
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative docking and molecular dynamics studies of molnupiravir (EIDD-2801): implications for novel mechanisms of action on influenza and SARS-CoV-2 protein targets.
    Istifli ES; Okumus N; Sarikurkcu C; Kuhn ER; Netz PA; Tepe AS
    J Biomol Struct Dyn; 2024 Sep; 42(15):8202-8214. PubMed ID: 37811782
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Could chlorophyllins improve the safety profile of beta-d-N4-hydroxycytidine versus N-hydroxycytidine, the active ingredient of the SARS-CoV-2 antiviral molnupiravir?
    Clark NF; Taylor-Robinson AW; Heimann K
    Ther Adv Drug Saf; 2022; 13():20420986221107753. PubMed ID: 35898799
    [No Abstract]   [Full Text] [Related]  

  • 36. Population pharmacokinetics of molnupiravir in adults with COVID-19: Lack of clinically important exposure variation across individuals.
    Bihorel S; Cao Y; Chawla A; Birger R; Maas BM; Gao W; Roepcke S; Sardella S; Humphrey R; Kondragunta S; Jayaraman B; Martinho M; Painter W; Painter G; Holman W; De Anda C; Brown ML; Johnson MG; Paschke A; Rizk ML; Stone JA
    CPT Pharmacometrics Syst Pharmacol; 2023 Dec; 12(12):1859-1871. PubMed ID: 37798914
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of the Potential for
    Sticher ZM; Lu G; Mitchell DG; Marlow J; Moellering L; Bluemling GR; Guthrie DB; Natchus MG; Painter GR; Kolykhalov AA
    Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31767721
    [No Abstract]   [Full Text] [Related]  

  • 38. Viral polymerase binding and broad-spectrum antiviral activity of molnupiravir against human seasonal coronaviruses.
    Wang Y; Li P; Solanki K; Li Y; Ma Z; Peppelenbosch MP; Baig MS; Pan Q
    Virology; 2021 Dec; 564():33-38. PubMed ID: 34619630
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biotransformation and brain distribution of the anti-COVID-19 drug molnupiravir and herb-drug pharmacokinetic interactions between the herbal extract Scutellaria formula-NRICM101.
    Chang CH; Peng WY; Lee WH; Lin TY; Yang MH; Dalley JW; Tsai TH
    J Pharm Biomed Anal; 2023 Sep; 234():115499. PubMed ID: 37302376
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sangivamycin is preferentially incorporated into viral RNA by the SARS-CoV-2 polymerase.
    Bennett RP; Yoluç Y; Salter JD; Ripp A; Jessen HJ; Kaiser SM; Smith HC
    Antiviral Res; 2023 Oct; 218():105716. PubMed ID: 37690700
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.